October 3, 2011
Astellas Pharma announced the results of a Japanese PIII study of the SGLT2 (sodium-glucose co-transporter) inhibitor ipragliflozin (development code: ASP1941) at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon on September 15...read more